Search
Xenon Pharmaceuticals Inc
XENEAdd to Watchlist
60.960USD
+0.660+1.09%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.89BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.09%
5 Days
+2.04%
1 Month
+15.04%
6 Months
+37.02%
Year to Date
+36.01%
1 Year
+83.28%
Key Figures
60.330Open
61.630High
1.46MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.51%Turnover Ratio
60.300Prev. Close
60.000Low
70.54MTurnover
LossP/E Static
4.40P/B
0.00%Div Yield TTM
-35.98%ROA
63.95052wk High
0.85Volume Ratio
-234.33MNet Profit
96.62MShares
-4.7092EPS TTM
0.63Beta
-37.53%ROE
28.19052wk Low
2.70%Amplitude
100.00%Gross Margin
5.89BMarket Cap
6.74Reward/Risk
2.05%Risk Rate
TradingKey Stock Score of Xenon Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Xenon Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 22 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 81.56.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xenon Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Xenon Pharmaceuticals Inc Highlights
StrengthsRisks
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.50M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 7.50M.
Fairly Valued
The company’s latest PE is -12.95, at a medium 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 257.33K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.01.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
81.563
Target Price
+35.26%
Upside Space
Xenon Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xenon Pharmaceuticals Inc Info
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Ticker SymbolXENE
CompanyXenon Pharmaceuticals Inc
CEOMortimer (Ian C)
Websitehttps://www.xenon-pharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Xenon Pharmaceuticals Inc (XENE)?
The current price of Xenon Pharmaceuticals Inc (XENE) is 60.96.
What is the symbol of Xenon Pharmaceuticals Inc?
The ticker symbol of Xenon Pharmaceuticals Inc is XENE.
What is the 52-week high of Xenon Pharmaceuticals Inc?
The 52-week high of Xenon Pharmaceuticals Inc is 63.95.
What is the 52-week low of Xenon Pharmaceuticals Inc?
The 52-week low of Xenon Pharmaceuticals Inc is 28.19.
What is the market capitalization of Xenon Pharmaceuticals Inc?
The market capitalization of Xenon Pharmaceuticals Inc is 5.89B.
Is Xenon Pharmaceuticals Inc (XENE) currently rated as Buy, Hold, or Sell?
According to analysts, Xenon Pharmaceuticals Inc (XENE) has an overall rating of Buy, with a price target of 81.56.
What is the Earnings Per Share (EPS TTM) of Xenon Pharmaceuticals Inc (XENE)?
The Earnings Per Share (EPS TTM) of Xenon Pharmaceuticals Inc (XENE) is -4.36.